fda statement bpc-157 compounding safety risks BIG NEWS FOR BPC 157 Today, the FDA's Pharmacy Advisory Committee voted 8 to 6 to recommend adding BPC 157 to the list of substances that may be eligible for pharmacy FDA's own advisory committee voted

FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! The FDA is reviewing which compounded peptides will be permitted for production by specialized pharmacies, threatening consumer access. MORE BELOW Federal health advisers are meeting to review a group of controversial chemicals called peptides, which have become a growing wellness trend. FULL STORY Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law

SKU: 78993072415 · From creatorsinfotech.com